Hearing · adults with CSOM
1 finding from 1 review
Resolution of ear discharge ‐ measured after 4 weeks · people (of any age) with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious complications · adults with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Suspected ototoxicity · adults with CSOM
1 finding from 1 review
Health‐related quality of life · people (of any age) with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ear pain (otalgia) or discomfort or local irritation · people (of any age) with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hearing · people (of any age) with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious complications · people (of any age) with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Suspected ototoxicity · people (of any age) with CSOM
1 finding from 1 review
Number of responders · IBD patients
IV iron sucrose showed no clear difference in number of responders ‐ active or inactive disease (6 weeks) compared with oral iron sulphate (low certainty).
1 finding from 1 review
Number of responders ‐ mild to moderate disease (12 weeks) · IBD patients
IV ferric carboxymaltose showed no clear difference in number of responders ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (low certainty).
1 finding from 1 review
Serious adverse events ‐ mild to moderate disease (16 weeks) · IBD patients
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review
Number of responders · IBD patients
IV iron isomaltoside showed no clear difference in number of responders ‐ remission or mild disease (8 weeks) compared with oral iron sulphate (low certainty).
1 finding from 1 review
Serious adverse events ‐ remission or mild disease (8 weeks) · IBD patients
It is very uncertain whether IV iron isomaltoside changes serious adverse events ‐ remission or mild disease (8 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review
Number of responders · IBD patients
It is very uncertain whether IM erythropoietin changes number of responders ‐ active disease (12 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
Serious adverse events · IBD patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of responders · IBD patients
Intravenous preparations may leads to higher number of responders compared with oral preparations (low certainty).
1 finding from 1 review
Serious adverse events ‐ mild to moderate disease (16 weeks) · IBD patients
It is very uncertain whether IV iron sucrose changes serious adverse events ‐ mild to moderate disease (20 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · IBD patients
Intravenous preparations may leads to lower withdrawal due to adverse events compared with oral preparations (low certainty).
1 finding from 1 review
All‐cause mortality ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found